Clinical Trials

Find a Clinical Trial

Enrolling Trials

71-80  of  125
►
Multicenter, Phase II Validation of a Nutritional Screening Tool for Critically Ill Children
Oelstrom, Matthew
Biology
Child
The specific aim of this study is to compare the phase I validated CHW/MCW Nutritional Screening Tool for Critically-Ill Children to the gold-standard SGNA, specifically comparing efficacy to identify malnourished pediatric patients or those at risk of becoming malnourished during critical care admissions.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer: The M&M Study
Gokalp Yasar, Demet
Treatment of Side Effects - Rectum
Adult
This is a prospective cohort study that examines the impact of myopenia on chemotherapy toxicity in overall survival (OS) in older adults with newly diagnosed metastatic colorectal cancer (CRC) receiving 5-Fluouracil (5FU)systemic chemotherapy. The study also explores the mediating influence of genetic variation in the association between myopenia and chemotherapy toxicity.
Craig, Chani L
(715) 358-1838
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
NHLBI-MDS,The National Myelodysplastic Syndromes Natural History Study
Onitilo, Adedayo A
Other Blood Cancers - Myelodysplastic Syndrome
Adult
Multi-center study enrolling patients suspected or newly diagnosed with myelodysplastic syndromes (MDS), myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) overlap disorder, or idiopathic cytopenia of undetermined significance (ICUS). Participants will be followed long term. Clinical data, blood, and tissue samples will be collected to establish a biorepository to facilitate the study of the natural history of MDS.
Bulgrin, Angela M
(715) 221-7261
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Eau Claire
2116 Craig Rd
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
NRG BR007-A Phase III Clinical Trial Evaluating De- Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
Abdelhadi, Kareem H
Breast - Breast
Adult
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Wilson, Anna E
(715) 858-6860
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Rice Lake
2501 Main
Stevens Point, WI  54481
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
NRG-BN003, Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Lawler, Benjamin E
Brain, Spinal Cord - Spinal Cord
Adult
This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.
Gallagher, Ashley M
(715) 387-7687
Diagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI  54476
MMC - Eau Claire
2116 Craig Rd
Eau Claire, WI  54701
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Rice Lake
2501 Main
Stevens Point, WI  54481
MMC - River Region at Stevens Point
,   
►
NRG-CC005-Five or Ten Year Colonoscopy for 1-2 Non- Advanced Adenomatous Polyps
Tanimu, Sabo B
Cancer Prevention - Rectum
Adult
FORTE is a colorectal cancer prevention study looking to determine how often participants who have had 1-2 small benign polyps removed during colonoscopy from their colon otherwise known as adenomatous polyps or adenomas should have repeat surveillance colonoscopies. The primary goal of FORTE is to compare the colorectal cancer rates between the two study groups (repeat colonoscopy at 5 and 10 years versus repeat colonoscopy at 10 years) to see if the rates are equivalent. If they are equivalent, then people in the future would likely be recommended to only undergo a 10-year exam and the 5-year exam may not be necessary. Participants will be asked to donate blood and stool samples and will be followed annually.
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
NRG-GI004, Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Yeboah, Isaac
Stomach, Intestine, Gut - Rectum
Adult
This randomized phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient DNA mismatch repair colorectal cancer that has spread to other places in the body. Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab and atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
NRG-GI008 - Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)
Husak, Michael
Stomach, Intestine, Gut - Rectum
Adult
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Wilson, Anna E
(715) 858-6860
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
NRG-GU008, Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy
Fagbemi, Seth O
Bladder, Prostate, Kidney - Prostate
Adult
This phase III trial studies how well adding apalutamide, abiraterone acetate, and prednisone to the usual hormone therapy and radiation therapy works compared to the usual hormone therapy and radiation therapy in treating patients with node-positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or slow the growth of prostate cancer cell growth by blocking the androgens. Abiraterone acetate blocks some of the enzymes needed for androgen production and may cause the death of prostate cancer cells that need androgens to grow. Prednisone may help abiraterone acetate work better by making tumor cells more sensitive to the drug. Adding apalutamide and abiraterone acetate with prednisone to the usual usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading or extend time without disease spreading compared to the usual approach.
Revels, Cheryl M
(715) 389-4177
Diagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI  54476
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Eau Claire
2116 Craig Rd
Eau Claire, WI  54701
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476
►
NRG-GU010-Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Onitilo, Adedayo A
Bladder, Prostate, Kidney - Prostate
Adult
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness. The Decipher risk score evaluates a prostate cancer tumor for its potential for spreading. In patients with low risk scores, this trial compares radiation therapy alone to the usual treatment of radiation therapy and hormone therapy (androgen deprivation therapy). Radiation therapy uses high energy x-rays or particles to kill tumor cells and shrink tumors. Androgen deprivation therapy blocks the production or interferes with the action of male sex hormones such as testosterone, which plays a role in prostate cancer development. Giving radiation treatment alone may be the same as the usual approach in controlling the cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy. In patients with higher Decipher gene risk, this trial compares the addition of darolutamide to usual treatment radiation therapy and hormone therapy, to usual treatment. Darolutamide blocks the actions of the androgens (e.g. testosterone) in the tumor cells and in the body. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading.
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
MMC - Eau Claire
2116 Craig Rd
Eau Claire, WI  54701
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Rice Lake
2501 Main
Stevens Point, WI  54481
MMC - River Region at Stevens Point
,   
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI  54476